@mesa_trt's estrogen monitoring claims, fact-checked

What did @mesa_trt actually say?

The creator's core argument is that when men go from low or no testosterone to supplementing it, the body converts that testosterone into estrogen through a process they call "rheumatase" (they mean aromatization), and this is "the worst possible thing." They also argue that doctors with experience in TRT should monitor estrogen and may need to titrate testosterone doses upward slowly in men who start with very low baseline levels.

Credit where it's due: the underlying point about aromatization and estrogen monitoring is clinically sound. But the framing does some real damage. Calling estrogen conversion "the worst possible thing" is both inaccurate and a bit alarmist. Estrogen is not the enemy. It plays necessary roles in male physiology, including bone density, cardiovascular function, and libido. The problem isn't estrogen itself. It's estrogen that's out of range.

Does the science back this up?

Yes, with significant caveats. Aromatization is well-documented. The enzyme aromatase converts testosterone to estradiol, and exogenous testosterone does increase this conversion. Men with higher baseline testosterone, more adipose tissue, or higher aromatase activity will convert more. This is real and worth monitoring.

Estrogen monitoring during TRT is supported by clinical practice guidelines. The American Urological Association and Endocrine Society both recommend periodic hormone panels during TRT, which typically include estradiol. Research by Finkelstein et al. (2013, New England Journal of Medicine) demonstrated that estradiol, not just testosterone, contributes to sexual function and body composition in men. That study actually rehabilitated estrogen's reputation in male health science.

The claim that slower titration is warranted for men with very low starting testosterone is reasonable in clinical practice, though the evidence base for a specific ramp-up protocol is limited. It reflects conservative clinical judgment more than a hard evidence standard.

What did they get wrong (or right)?

The biggest error is the language around estrogen. Saying conversion to estrogen is "the worst possible thing" misrepresents physiology and could push viewers toward unnecessary fear of estradiol or toward unsupervised aromatase inhibitor use, which carries real risks including bone loss and lipid changes.

They also mispronounced aromatization as "rheumatase," which is a meaningless term. That's a minor verbal stumble, but on a health platform, precision matters.

What they got right: estrogen monitoring during TRT is genuinely important. Elevated estradiol in men can cause gynecomastia, fluid retention, and mood changes. Low estradiol in men on TRT (often caused by overuse of aromatase inhibitors) can cause joint pain, low libido, and bone loss. Both ends of that spectrum are problems. The recommendation to work with an experienced clinician is also correct, even if the reasoning is incomplete.

What should you actually know?

Estrogen in men is not optional. A 2013 study by Finkelstein et al. in the NEJM showed that estradiol deficiency independently caused sexual dysfunction in men, separate from testosterone levels. Crashing your estrogen with aggressive aromatase inhibitor use is not a solution. It's a different problem.

The appropriate estradiol range for men on TRT is typically cited as 20 to 40 pg/mL on a sensitive assay, though individual response varies. Routine monitoring, usually every 3 to 6 months once stable, is standard practice. If a clinician is starting you on TRT and not checking estradiol, that is a gap worth raising.

Men with low baseline testosterone do sometimes benefit from gradual dose titration, but this is not universal. The clinical rationale relates more to tolerability and cardiovascular adaptation than to estrogen specifically. A good clinician will individualize the approach rather than apply a blanket rule.

• Estrogen monitoring on TRT: clinically supported and recommended by major guidelines.
• The framing of estrogen as inherently bad: not supported by evidence and potentially harmful.
• Slow titration for very low baseline testosterone: reasonable clinical caution, not firmly evidence-based.